NCI-H3122 Xenograft Model Service for NSCLC

The NCI-H3122 xenograft model, harboring the canonical EML4-ALK variant 1 fusion in an EGFR-wild-type, KRAS-wild-type background, represents the preclinical gold standard for evaluating ALK-directed tyrosine kinase inhibitors in lung adenocarcinoma. Alfa Cytology provides authenticated NCI-H3122 cell line-derived xenograft services with documented EML4-ALK fusion status, enabling robust preclinical assessment of first-, second-, and third-generation ALK inhibitors as well as combination strategies targeting acquired resistance.

Overview of NCI-H3122 Xenograft Model for NSCLC

NCI-H3122 was established from a pleural effusion metastasis of lung adenocarcinoma in a 54-year-old Caucasian male patient. The cell line carries the EML4-ALK variant 1 fusion (E13;A20), which results from the juxtaposition of echinoderm microtubule-associated protein-like 4 (EML4) exon 13 with anaplastic lymphoma kinase (ALK) exon 20, producing a constitutively active chimeric tyrosine kinase. Its wild-type EGFR, KRAS, and BRAF status isolates ALK as the sole dominant oncogenic driver, rendering the model exquisitely sensitive to ALK inhibition and an ideal platform for studying ALK-addicted tumor biology.

Fig 1. Iruplinalkib dose-dependently inhibited NCI-H3122 EML4-ALK xenograft growth with efficacy comparable to brigatinib and superior to crizotinib/ceritinib; intratumoral p-STAT3 suppression was observed in vivo but not in vitro, highlighting the H3122 CDX model's value for capturing tumor-microenvironment effects. (Yang, Yingying, et al., 2023)

When engrafted subcutaneously in immunodeficient mice, NCI-H3122 forms rapidly growing tumors with predictable kinetics, becoming palpable within 7–10 days and exhibiting robust dose-dependent responses to crizotinib. The model has been extensively validated in regulatory pharmacology studies, demonstrating inhibition of EML4-ALK phosphorylation, downstream STAT3/ERK/AKT signaling, Ki-67 proliferation markers, and induction of activated caspase-3 upon ALK inhibitor treatment. Consequently, the NCI-H3122 xenograft serves as an indispensable benchmark for evaluating novel ALK inhibitors, next-generation compounds overcoming gatekeeper mutations, and combination regimens that forestall acquired resistance.

Cell Line Information: NCI-H3122

The NCI-H3122 cell line was obtained from the NCI Repository of Tumor Cell Lines (Frederick, MD, USA) and is catalogued in Cellosaurus (CVCL_5160). Its well-documented genotype and phenotype support high-confidence preclinical translation:

Our Services

Alfa Cytology maintains NCI-H3122 under authenticated culture conditions and constructs xenografts with verified EML4-ALK variant 1 fusion status, offering study designs that span monotherapy dose-response characterization, combination regimen screening, and longitudinal pharmacodynamic profiling to advance your ALK-positive NSCLC therapeutic pipeline.

Workflow of NCI-H3122 Xenograft Model Construction

NCI-H3122 xenograft construction follows a standardized protocol optimized for ALK-addicted epithelial cells, ensuring reproducible engraftment and robust pharmacological readouts aligned with regulatory pharmacology standards. The workflow proceeds through six integrated phases:

1. Cell Expansion and Authentication: NCI-H3122 cells are propagated in RPMI-1640 with 10% FBS. Each batch is verified by STR profiling, mycoplasma testing, and EML4-ALK fusion confirmation by RT-PCR or targeted sequencing prior to implantation.
2. Harvest and Matrigel Preparation: Adherent cultures are detached with trypsin-EDTA, washed, and counted. Cells are resuspended at 2 × 10⁷ cells/mL in a 1:1 mixture of serum-free RPMI-1640 and high-concentration Matrigel to facilitate tumor take and stromal interaction.
3. Subcutaneous Engraftment: A 100 µL suspension containing 2 × 10⁶ viable cells is injected subcutaneously into the hind flank of immunodeficient mice. Tumor nodules typically become palpable within 7–10 days post-injection.
4. Tumor Monitoring and Cohort Randomization: Tumor dimensions are measured twice weekly with electronic calipers, with volume derived from the formula length × width² × 0.4. Upon reaching 100–150 mm³, mice are randomized into treatment groups stratified by tumor volume and body weight.
5. Dosing and In-Life Assessments: Test compounds are administered via the designated route and schedule. Tumor volumes and body weights are recorded at defined intervals throughout the dosing phase. Optional blood draws support PK/PD correlation analysis.
6. Terminal Procedures and Sample Processing: At study endpoint, tumors are excised, weighed, and imaged. Tissues are fixed in 10% neutral buffered formalin for H&E and IHC analysis, with portions snap-frozen in liquid nitrogen for downstream genomic or proteomic studies.

Fig 2. NCI-H3122 xenograft model construction workflow.

Case Study-NCI-H3122 Xenograft Model Development

In a preclinical program evaluating a novel second-generation ALK inhibitor, NCI-H3122 xenografts were established in athymic nude mice and dosed orally once daily for 21 days. The investigational compound produced dose-dependent tumor growth inhibition across multiple treatment arms, with the highest dose cohort demonstrating sustained suppression relative to vehicle-treated controls. Post-study immunohistochemistry revealed diminished phospho-ALK and phospho-STAT3 staining in responder tumors, alongside reduced Ki-67 proliferation indices and elevated cleaved caspase-3 expression indicative of apoptosis induction. These preclinical observations provided pharmacodynamic validation and supported the compound's advancement into extended tolerability and resistance mechanism studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for NCI-H3122 xenograft studies ensures access to a genetically characterized ALK-addicted model managed under rigorous quality standards.

• Every NCI-H3122 batch is validated by STR analysis and confirmed for EML4-ALK variant 1 fusion status before study initiation.
• We provide flexible dosing paradigms including oral gavage, intravenous, and intraperitoneal administration with customizable frequency and duration.
• Tumor growth data are captured with electronic calipers and optional bioluminescence imaging for real-time longitudinal monitoring.
• All in vivo work is performed in AAALAC-accredited vivaria under IACUC-reviewed protocols with full veterinary support.
• Comprehensive study reports include statistical analysis, individual animal data, and publication-ready histopathology images with phospho-ALK staining.

Contact Us

To advance your ALK-positive NSCLC therapeutic candidate through a validated EML4-ALK preclinical model, contact Alfa Cytology today. Our scientific team will collaborate with you to design a tailored NCI-H3122 xenograft program that aligns with your target product profile and regulatory milestones.

For research use only. Not intended for any clinical use.